Nicox SA

Health careCOXFR0013018124

RSS feed

A. is a French ophthalmology company developing treatments to maintain vision and improve ocular health.

Filings

60 filings

All Inside information53 AGM documents2 Earnings release2 Half-year financial report2 Threshold crossing1

01/07/2026
Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
Inside informationFR
23/06/2026
Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
Inside informationFR
18/06/2026
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Inside informationFR
08/06/2026
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
Inside informationFR
03/06/2026
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
Inside informationFR
30/04/2026
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
Inside informationFrench
30/04/2026
Nicox Provides Full Year 2025 Financial Results and Corporate Update
Earnings release
20/04/2026
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
Inside informationFR
24/02/2026
Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
Inside informationFR
16/02/2026
Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
Inside informationFR
12/02/2026
Nicox confirme son éligibilité au PEA-PME
Inside informationFrench
10/02/2026
Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
Inside informationFR
20/01/2026
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
Inside informationFR
05/01/2026
Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
Inside informationFR
16/12/2025
Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
Inside informationFR
23/10/2025
Nicox Provides First Half 2025 Financial Results
Half-year financial reportFR
02/10/2025
Nicox’s NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
Inside informationFR
04/09/2025
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
Inside informationFR
26/08/2025
Nicox Announces Shareholder Q&A Webpage Available
Inside informationFR
12/08/2025
Franchissement de seuils
Threshold crossingFrench
08/08/2025
Nicox Extends Existing Flexible Equity Financing
Inside informationFR
05/08/2025
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Inside informationFR
17/07/2025
Nicox and Kowa Sign Key Agreement worth up to €191.5 million for Exclusive Rights to Glaucoma Treatment NCX 470 in U.S. and all Unlicensed Territories
Inside information
30/06/2025
Nicox Announces Last Patient Completes the NCX 470 Denali Phase 3 Clinical Trial
Inside informationFR
06/06/2025
Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
AGM documentsFR
27/05/2025
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
Inside informationFR
30/04/2025
Nicox : Résultats financiers de l’année 2024
Inside informationFrench
30/04/2025
Nicox Provides Full Year 2024 Financial Results
Earnings release
19/03/2025
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial
Inside informationFR
06/03/2025
Nicox Extends Cash Runway into Q4 2025
Inside informationFR
03/03/2025
Nicox Presents New Analysis from the NCX 470 Mont Blanc Trial and Provides Development Update
Inside informationFR
28/01/2025
Nicox Announces Scientific Presentation and Conference Attendance in H1 2025
Inside informationFR
22/01/2025
Nicox confirme son éligibilité au PEA-PME
Inside informationFrench
21/01/2025
Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights
Inside informationFR

About

ISIN: FR0013018124
Ticker: COX
LEI: 969500EZGEO9W4JXR353
Sector: Health care
Founded: 1996
Country of registration: FR
Last filing: 01/07/2026, 07:30

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive